{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T08:22:57Z","timestamp":1704961377500},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Acute lymphoblastic leukemia (ALL) secondary to multiple myeloma (MM) is rare. Here we report a rare case of secondary ALL transformed from MM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 64-year-old woman was diagnosed as MM IgG light chain type in 2001. She achieved complete remission after 2 cycles of therapy, and received maintenance therapy with thalidomide. The patient suffered from MM relapse in September 2011. Bone marrow examination showed that the percentage of primary lymphocytes was 59%, indicating ALL-L2 (Pre-B-ALL). The patient reached complete remission after 1 cycle of chemotherapy, and has been maintained for more than 6 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Immunophenotyping analysis revealed that the abnormal cell population accounted for approximately 66% which expressed HLA-DR, CD4, CD22, CD33, CD34, and cCD79a. These results indicated acute B lymphoblastic leukemia. Chromosome presented 47, XX, +5, \u22127, +19. Leukemia fusion gene analysis demonstrated positive <jats:italic toggle=\"yes\">EVI1<\/jats:italic> and negative <jats:italic toggle=\"yes\">IgH<\/jats:italic> and <jats:italic toggle=\"yes\">TCR<\/jats:italic> gene rearrangement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient accepted 1 cycle of VDCLP chemotherapy and reached complete remission, followed with consolidation therapies with VDCLP, MA, CAG and other chemotherapy regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>This patient has maintained CR1 of ALL for more than 6 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Even secondary lymphoblastic leukemia has been rarely reported in patients with MM, we still need perform bone marrow examination, flow cytology, and gene tests, especially during maintenance therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014018","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T01:09:34Z","timestamp":1546564174000},"page":"e14018","source":"Crossref","is-referenced-by-count":2,"title":["Multiple myeloma secondary to acute lymphoblastic leukemia"],"prefix":"10.1097","volume":"98","author":[{"given":"Tonglin","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/10428194.2016.1217527","article-title":"Secondary malignancies in patients with multiple myeloma, Waldenstrom macroglobulinemia and monoclonal gammopathy of undetermined significance","volume":"58","author":"Castillo","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.5301\/tj.5000377","article-title":"Three patients with multiple myeloma developing secondary lymphoblastic leukemia: case reports and review of the literature","volume":"102","author":"Junxun","year":"2016","journal-title":"Tumori"},{"key":"R3-20230914","first-page":"593","article-title":"Secondary acute lymphoblastic leukaemia in a multiple myeloma patient","volume":"16","author":"Piszcz","year":"2012","journal-title":"Contemp Oncol (Pozn)"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hon.2248","article-title":"Lenalidomide and secondary acute lymphoblastic leukemia: a case series","volume":"35","author":"Tan","year":"2017","journal-title":"Hematol Oncol"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1561::AID-CNCR18>3.0.CO;2-W","article-title":"Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479","volume":"79","author":"Oken","year":"1997","journal-title":"Cancer"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/sj.leu.2402918","article-title":"High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities","volume":"17","author":"Ishizawa","year":"2003","journal-title":"Leukemia"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/10428190109057981","article-title":"Therapy related leukemias: susceptibility, prevention and treatment","volume":"41","author":"Leone","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/sj.leu.2403587","article-title":"Acute lymphoblastic leukemia after tandem autologous stem cell transplantations for multiple myeloma","volume":"19","author":"Lau","year":"2005","journal-title":"Leukemia"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00277-008-0680-8","article-title":"Early onset of acute lymphoblastic leukemia with MLL rearrangement after autologous stem cell transplantation for multiple myeloma","volume":"88","author":"Ueda","year":"2009","journal-title":"Ann Hematol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12185-009-0397-z","article-title":"Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma","volume":"90","author":"Igarashi","year":"2009","journal-title":"Int J Hematol"},{"key":"R11-20230914","first-page":"2101","article-title":"High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities","volume":"28","author":"Groschel","year":"2010","journal-title":"Clin Oncol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1309\/AJCPOP7APGDT9JIU","article-title":"Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens","volume":"138","author":"Reddi","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"44","DOI":"10.5858\/2010-0387-RAR.1","article-title":"Multiparameter flow cytometry in the diagnosis and management of acute leukemia","volume":"135","author":"Peters","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"Moricke","year":"2008","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201901040-00072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:07:16Z","timestamp":1694714836000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201901040-00072"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014018","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}